OTCMKTS:NMUSNemus Bioscience Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nemus Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.05 +0.01 (+25.00 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$0.04Now: $0.05▼$0.0550-Day Range$0.04MA: $0.11▼$0.1952-Week Range$0.05Now: $0.05▼$0.74Volume3.02 million shsAverage Volume494,554 shsMarket Capitalization$6.70 millionP/E RatioN/ADividend YieldN/ABeta-0.04 ProfileChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nemus Bioscience. Previous Next 3.2 Community Rank Outperform VotesNemus Bioscience has received 99 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNemus Bioscience has received 58 “underperform” votes. (Add your “underperform” vote.)Community SentimentNemus Bioscience has received 63.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nemus Bioscience and other stocks. Vote “Outperform” if you believe NMUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NMUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNemus Bioscience does not currently pay a dividend.Dividend GrowthNemus Bioscience does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nemus Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Nemus Bioscience is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryCannabis SectorMedical Current SymbolOTCMKTS:NMUS Previous Symbol CUSIPN/A CIKN/A Webwww.nemusbioscience.com Phone949-396-0330Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-0.42Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-19,190,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-924.42%Miscellaneous EmployeesN/A Outstanding Shares133,910,000Market Cap$6.70 million Next Earnings DateN/A OptionableNot Optionable $0.05 +0.01 (+25.00 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NMUS News and Ratings via Email Sign-up to receive the latest news and ratings for NMUS and its competitors with MarketBeat's FREE daily newsletter. Nemus Bioscience (OTCMKTS:NMUS) Frequently Asked Questions How were Nemus Bioscience's earnings last quarter? Nemus Bioscience Inc (OTCMKTS:NMUS) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter. View Nemus Bioscience's earnings history. Has Nemus Bioscience been receiving favorable news coverage? News stories about NMUS stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nemus Bioscience earned a news impact score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Nemus Bioscience. Who are some of Nemus Bioscience's key competitors? Some companies that are related to Nemus Bioscience include Canopy Growth (WEED), Canopy Growth (CGC), Innovative Industrial Properties (IIPR), GrowGeneration (GRWG), OrganiGram (OGI), Emblem (EMC), ICC Labs (ICC), Bioventix (BVXP), 22nd Century Group (XXII), KushCo (KSHB), General Cannabis (CANN), Grow Capital (GRWC), Terra Tech (TRTC), mCig (MCIG) and Leafbuyer Technologies (LBUY). View all competitors. What other stocks do shareholders of Nemus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Canopy Growth (CGC), Emerald Health Therapeutics (EMHTF), KushCo (KSHB), Medmen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Terra Tech (TRTC), 22nd Century Group (XXII), mCig (MCIG) and Cronos Group (CRON). Who are Nemus Bioscience's key executives? Nemus Bioscience's management team includes the following people: Dr. Brian S. Murphy, CEO, Chief Medical Officer & Director (Age 61)Dr. Avtar S. Dhillon, Exec. Chairman (Age 57)Mr. Douglas A. Cesario, Chief Financial Officer (Age 44)Ms. Wendy Cunning, VP of Bus. Operations What is Nemus Bioscience's stock symbol? Nemus Bioscience trades on the OTCMKTS under the ticker symbol "NMUS." How do I buy shares of Nemus Bioscience? Shares of NMUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nemus Bioscience's stock price today? One share of NMUS stock can currently be purchased for approximately $0.05. How big of a company is Nemus Bioscience? Nemus Bioscience has a market capitalization of $6.70 million. What is Nemus Bioscience's official website? The official website for Nemus Bioscience is www.nemusbioscience.com. How can I contact Nemus Bioscience? Nemus Bioscience's mailing address is 130 NORTH MARINA DRIVE, LONG BEACH CA, 90803. The biopharmaceutical company can be reached via phone at 949-396-0330. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
